Botanix presents at the Shaw and Partners Investor Seminar
Botanix showcased the BTX1503 acne program and initiation of first clinical trial within coming weeks Sydney 4 May March 2017: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) is pleased to release a new presentation, which Botanix Executive Director, Matt Callahan, presented at the Shaw and Partners Investor Seminar last evening. The presentation at the seminar was used to provide an update on the Company’s lead clinical development program, involving the use of synthetic cannabidiol for the treatment of acne. Botanix was also able to showcase its rapid operational progress towards first clinical studies, which are expected to commence in the coming weeks. Completion of this first study will be closely followed by an Australian pilot study in acne patients.
BOT Price at posting:
5.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)